Incyte
| Public | |
| Traded as | NASDAQ: INCY |
| Industry | pharmaceutical company |
| Founded | 1991 |
| Headquarters | Wilmington, Delaware, United States |
Key people | Hervé Hoppenot (President and CEO, 2014) |
| Revenue | ~US$94.5 million (2011) |
| ~(US$186.5 million) (2011) | |
| Total assets | ~US$329 million (2011) |
| Total equity | ~(US$227 million) (2011) |
Number of employees | ~600[1] |
| Website |
www |
|
Footnotes / references [2] | |
Incyte, Corp is a pharmaceutical company based in Alapocas, Delaware.[3] Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi.[3] The company was founded in Palo Alto, California in 1991 and went public in 1993.[1]
The company is working on an investigational Phase III drug for rheumatoid arthritis in partnership with Eli Lilly, called baricitinib.[4]
Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced hepatocellular carcinoma[5]
History
In 2014, Incyte named Hervé Hoppenot president and CEO.[6] Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.[6]
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[7]
References
- 1 2 Scott Goss (2 Mar 2015). "Incyte is Delaware Bio Company of the Year, again". delawareonline.com. Retrieved 2 Mar 2015.
- ↑ Incyte Corporation (2012), Form 10-K (SEC filing), Incyte Corporation (published February 22, 2012), Commission File Number: 0-27488, retrieved May 6, 2012
- 1 2 Natoli, Cori Anne (May 5, 2012), "Incyte looks to ride on drug's success", The News Journal, retrieved May 6, 2012
- ↑ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Retrieved 2 Mar 2015.
- ↑ "Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. Retrieved 2015-12-29.
- 1 2 "People". Gen. Eng. Biotechnol. News (paper) 34 (4). February 15, 2014. p. 41.
- ↑ http://www.genengnews.com/gen-news-highlights/incyte-to-co-develop-hengrui-s-shr-1210-in-up-to-795m-deal/81251695/